Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
γ-Butyrobetaine (also known as gamma-butyrobetaine or GBB) is a naturally occurring zwitterionic compound and the immediate endogenous biosynthetic precursor to L-carnitine. It is synthesized from lysine and methionine and is subsequently converted into L-carnitine by the enzyme gamma-butyrobetaine dioxygenase (BBOX1). γ-Butyrobetaine is widely used as a dietary supplement (often marketed as 'pre-carnitine' or 'GBB') in sports nutrition and weight loss products to enhance mitochondrial fatty acid oxidation, energy production, and thermogenesis. Additionally, it is studied as a gut microbial metabolite of L-carnitine that can be converted into the pro-atherosclerotic compound trimethylamine N-oxide (TMAO).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on γ-butyrobetaine.